Vertex Pharmaceuticals (VRTX) reported Q2 adjusted earnings late Monday of $4.73 per diluted share, up from $4.52 a year earlier.

Analysts polled by FactSet expected $4.74.

Revenue for the quarter ended June 30 was $3.33 billion, up from $2.96 billion a year earlier.

Analysts expected $3.23 billion.

For the full-year 2026, the company raised its revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion previously. Analysts expect $13.06 billion.